A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

• Status: Recruiting
• Trial end date: 2026-01-16
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severely active ulcerative colitis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen Research & Development, LLC

Criteria

Inclusion Criteria:

• Signed informed consent form 18 years of age or older

• Documented diagnosis of ulcerative colitis (UC) of at least 12 weeks prior to screening

• Moderately to severely active UC as per the modified Mayo score

• Demonstrated inadequate response to or intolerance of conventional therapy and/or advanced therapy as defined in the protocol

Exclusion Criteria:

• Participants with current or prior diagnosis of fulminant colitis and/or toxic megacolon

• UC limited to rectum only or to less than (<) 15 centimeters (cm) of colon

• Presence of a stoma

• Presence or history of fistula

• History of extensive colonic resection (example, <30 cm of colon remaining)

• Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, Crohn's colitis or clinical findings suggestive of Crohn's disease